IV 
118TH CONGRESS 
1ST SESSION 
H. RES. 367 
Designating the week of May 1, 2023, through May 7, 2023, as ‘‘Tardive 
Dyskinesia Awareness Week’’. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2023 
Mr. PETERS (for himself, Mr. BILIRAKIS, and Mr. BEAN of Florida) sub-
mitted the following resolution; which was referred to the Committee on 
Energy and Commerce 
RESOLUTION 
Designating the week of May 1, 2023, through May 7, 2023, 
as ‘‘Tardive Dyskinesia Awareness Week’’. 
Whereas many people with serious, chronic mental illness, 
such as schizophrenia and other schizoaffective disorders, 
bipolar disorder, or severe depression, require treatment 
with medications that work as dopamine receptor block-
ing agents (referred to in this preamble as ‘‘DRBAs’’), 
including antipsychotics; 
Whereas, while ongoing treatment with DRBAs can be very 
helpful, and even lifesaving, for many people it can also 
lead to tardive dyskinesia; 
Whereas many people who have gastrointestinal disorders, in-
cluding gastroparesis, nausea, and vomiting, also require 
treatment with DRBAs; 
VerDate Sep 11 2014 
01:01 May 06, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR367.IH
HR367
pbinns on DSKJLVW7X2PROD with $$_JOB
•HRES 367 IH 
Whereas studies suggest that the overall risk of developing 
tardive dyskinesia after taking DRBAs is between 10 and 
30 percent; 
Whereas it is estimated that over 600,000 people in the 
United States suffer from tardive dyskinesia; 
Whereas, according to the National Alliance for Mental Ill-
ness, 1 in every 4 patients receiving long-term treatment 
with an antipsychotic medication will experience tardive 
dyskinesia; 
Whereas years of difficult and challenging research have re-
sulted in recent scientific breakthroughs, with 2 new 
treatments for tardive dyskinesia approved by the Food 
and Drug Administration of the Department of Health 
and Human Services; 
Whereas tardive dyskinesia is often unrecognized, and pa-
tients 
suffering 
from 
the 
illness 
are 
commonly 
misdiagnosed; 
Whereas regular screening for tardive dyskinesia in patients 
taking DRBA medications is recommended by the Amer-
ican Psychiatric Association; 
Whereas patients suffering from tardive dyskinesia often suf-
fer embarrassment due to abnormal and involuntary 
movements, which leads them to withdraw from society 
and increasingly isolate themselves as the disease pro-
gresses; 
Whereas caregivers of patients with tardive dyskinesia face 
many challenges and are often responsible for the overall 
care of the tardive dyskinesia patient; and 
Whereas the House of Representatives can raise awareness of 
tardive dyskinesia in the public and medical community: 
Now, therefore, be it 
VerDate Sep 11 2014 
01:01 May 06, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR367.IH
HR367
pbinns on DSKJLVW7X2PROD with $$_JOB
•HRES 367 IH 
Resolved, That the House of Representatives— 
(1) expresses support for the designation of 
‘‘Tardive Dyskinesia Awareness Week’’; and 
(2) encourages each individual in the United 
States to become better informed about and aware 
of tardive dyskinesia. 
Æ 
VerDate Sep 11 2014 
01:01 May 06, 2023
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR367.IH
HR367
pbinns on DSKJLVW7X2PROD with $$_JOB